United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o), verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - trandolapril 4 mg - trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration ). in using trandolapril and verapamil hydrochloride extended-release tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see warnings - neutropenia/agranulocytosis ). trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients who are hypersensitive to any ace inhibitor or verapamil. because of the verapamil component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in: because of the trandolapril component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme (ace) inhibitor. do not co-administer aliskiren with trandolapril and verapamil hydrochloride extended-release tablets in patients with diabetes (see precautions - drug interactions ). trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer trandolapril and verapamil hydrochloride extended-release tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings ).

United States - English - NLM (National Library of Medicine)

greenstone llc - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o), verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - trandolapril 2 mg - trandolapril/verapamil hydrochloride er tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration ). in using trandolapril/verapamil hydrochloride er tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see warnings - neutropenia/agranulocytosis ). trandolapril/verapamil hydrochloride er tablets are contraindicated in patients who are hypersensitive to any ace inhibitor or verapamil. because of the verapamil component, trandolapril/verapamil hydrochloride er tablets are contraindicated in: - severe left ventricular dysfunction (see warnings ). - hypotension (systolic pressure less than 90 mmhg) or cardiogenic shock. - sick sinus syndrome (exce

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o) - trandolapril 4 mg - trandolapril tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema, and in patients with a history of angioedema related to previous treatment with an ace inhibitor.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - enalaprilat dihydrate (unii: gv0o7es0r3) (enalaprilat anhydrous - unii:q508q118jm) - enalaprilat 1.25 mg in 1 ml - enalaprilat injection, usp is indicated for the treatment of hypertension when oral therapy is not practical. enalaprilat injection, usp has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. in using enalaprilat injection, usp, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection, usp does not have a similar risk. (see warnings.) in considering use of enalaprilat injection, usp, it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (see warnings, angioedema ). enalaprilat injection, usp is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o) - trandolapril 1 mg - trandolapril tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. trandolapril tablets are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of trandolapril to caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see clinical pharmacology -heart failure or left-ventricular dysfunction post myocardial infarction for details of the survival trial). trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an ace i

United States - English - NLM (National Library of Medicine)

unit dose services - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 2.5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see clinical pharmacology, for details and limitations of survival trials.) in using enalapril maleate, consideration should be given to t

United States - English - NLM (National Library of Medicine)

stat rx usa llc - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate 10 mg

United States - English - NLM (National Library of Medicine)

rebel distributors corp - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril 5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials.

United States - English - NLM (National Library of Medicine)

med health pharma, llc - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril maleate 2.5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ?35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials.

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) - enalapril 5 mg - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trial